Analyzing the Pulmonary Arterial Hypertension Market Landscape … – Digital Journal

PRESS RELEASE

Published May 5, 2023

The Pulmonary Arterial Hypertension market report provides current treatment practices, Pulmonary Arterial Hypertension emerging drugs, Pulmonary Arterial Hypertension market share of the individual therapies, current and forecasted epidemiology in 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032. Pulmonary Arterial Hypertension Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities.

Recent Developmental Activities in the Pulmonary Arterial Hypertension Treatment Landscape

Explore more information about the Latest Drugs Launch, New Breakthroughs of Drugs or Therapies Approaches, Treatment Practices, and Forecasted Epidemiology @ Pulmonary Arterial Hypertension Market Size Report

Pulmonary Arterial Hypertension Overview

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension that is characterized by elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.

Key Takeaways from the Pulmonary Arterial Hypertension Market Report

Pulmonary Arterial Hypertension Epidemiology Segmentation in the 7MM

Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ Pulmonary Arterial Hypertension Epidemiological Insights

Pulmonary Arterial Hypertension Treatment Market

Currently approved Pulmonary Arterial Hypertension treatments target several main pathways that primarily promote dilation of the pulmonary vessels to reduce pulmonary vascular resistance. These therapies have been used alone or in combination to improve exercise capacity and slow the progression of the disease. However, no existing therapy directly addresses the underlying cellular proliferation that leads to increased pulmonary arterial pressure. In PAH, signaling via BMPR-II is imbalanced, allowing greater influence from the adjacent activin receptor pathway, further promoting cellular proliferation and vascular remodeling.

Pulmonary Arterial Hypertension Market Therapeutics

The Pulmonary Arterial Hypertension market therapeutic is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the treatment of Pulmonary Arterial Hypertension. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of PAH. LetairisVolibris (GlaxoSmithKline plcGilead Science), Opsumit (Actelion Pharmaceuticals Ltd), and Tracleer (Actelion Pharmaceuticals Ltd) are mostly recommended endothelin receptor antagonists being used for the treatment of Pulmonary Arterial Hypertension. These antagonists act by relaxing blood vessels and inhibiting the proliferation and remodeling of blood vessels.

Learn more about the FDA-approved drugs for Pulmonary Arterial Hypertension @ Pulmonary Arterial Hypertension Market Drivers and Barriers

Scope of the Pulmonary Arterial Hypertension Market Report

Discover more about Pulmonary Arterial Hypertension Drugs in development @ Pulmonary Arterial Hypertension Emerging Drugs and Companies

Table of Content

13 Key Opinion Leaders Views

14 SWOT Analysis

15 Pulmonary Arterial Hypertension Unmet Needs

16 Pulmonary Arterial Hypertension Market Access and Reimbursement

Got Queries? Reach out for more information about the Patient Population, Treatment Algorithm, Unmet Needs, and Emerging Drugs of the report @ Pulmonary Arterial Hypertension Market Dynamics Report

List of Top Selling Market Research Reports 2023

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

[emailprotected]

Follow this link:
Analyzing the Pulmonary Arterial Hypertension Market Landscape ... - Digital Journal